{
    "ticker": "GHRS",
    "name": "GH Research PLC",
    "description": "GH Research PLC is a biopharmaceutical company dedicated to developing innovative treatments for mental health disorders. Established in 2019, the company focuses on harnessing the therapeutic potential of psychedelic compounds, particularly 5-MeO-DMT, to address unmet medical needs in conditions such as treatment-resistant depression. GH Research aims to transform the treatment landscape for mental health by conducting rigorous clinical trials to validate the efficacy and safety of its drug candidates. The company is committed to advancing research in psychedelics and is positioned at the forefront of this emerging field, collaborating with leading researchers and institutions to explore the benefits of these compounds. GH Research's mission is to improve patient outcomes through pioneering therapies that can offer rapid and lasting relief from debilitating symptoms. With a strong pipeline of clinical programs, GH Research is working diligently to bring innovative solutions to market that can enhance the quality of life for patients suffering from severe mental health conditions.",
    "industry": [
        "Biopharmaceuticals",
        "Mental Health"
    ],
    "headquarters": "Dublin, Ireland",
    "founded": "2019",
    "website": "https://www.ghresearchplc.com",
    "ceo": "Dr. Anwar J. M. J. K. M. Al-Sukhni",
    "social_media": {
        "twitter": "https://twitter.com/GHResearchPLC",
        "linkedin": "https://www.linkedin.com/company/gh-research-plc/"
    },
    "investor_relations": "https://www.ghresearchplc.com/investors",
    "key_executives": [
        {
            "name": "Dr. Anwar J. M. J. K. M. Al-Sukhni",
            "position": "CEO"
        },
        {
            "name": "Dr. Nuno Ribeiro",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Trials",
            "products": [
                "5-MeO-DMT for treatment-resistant depression"
            ]
        }
    ],
    "seo": {
        "meta_title": "GH Research PLC | Innovating Mental Health Treatments",
        "meta_description": "GH Research PLC is focused on developing transformative therapies for mental health disorders using psychedelics. Explore our innovative research and commitment to patient care.",
        "keywords": [
            "GH Research",
            "Mental Health",
            "Psychedelics",
            "5-MeO-DMT",
            "Biopharmaceuticals",
            "Treatment-Resistant Depression"
        ]
    },
    "faq": [
        {
            "question": "What is GH Research known for?",
            "answer": "GH Research is known for developing innovative treatments for mental health disorders using psychedelic compounds."
        },
        {
            "question": "Who is the CEO of GH Research?",
            "answer": "Dr. Anwar J. M. J. K. M. Al-Sukhni is the CEO of GH Research PLC."
        },
        {
            "question": "Where is GH Research headquartered?",
            "answer": "GH Research is headquartered in Dublin, Ireland."
        },
        {
            "question": "What are GH Research's main products?",
            "answer": "GH Research's main product is 5-MeO-DMT, which is being investigated for treatment-resistant depression."
        },
        {
            "question": "When was GH Research founded?",
            "answer": "GH Research was founded in 2019."
        }
    ],
    "competitors": [
        "ATAI",
        "CMPS",
        "MAPS",
        "TRYP"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}